June Sung Lee

Dr. June Sung Lee

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
JKJong Hoon Kim
Jong Hoon Kim
JLJune Sung Lee
June Sung Lee
SLSeuk Hyun Lee
Seuk Hyun Lee
WBWon Ki Bae
Won Ki Bae
NKNam-Hoon Kim
Nam-Hoon Kim
YMYoung-Soo Moon
Young-Soo Moon
Dilutional hyponatremia associated with liver cirrhosis is caused by impaired free water clearance. Several studies have shown that serum sodium levels correlate with survival in cirrhotic patients. Little is known, however, regarding the relationship between the degree of dilutional hyponatremia and development of cirrhotic complications. The aim of this study was to evaluate the association between the serum sodium level and the severity of complications in liver cirrhosis. Data of inpatients with cirrhotic complications were collected retrospectively. The serum sodium levels and severity of complications of 188 inpatients were analyzed. The prevalence of dilutional hyponatremia, classified as serum sodium concentrations of

15 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
JPJung Gil Park
Jung Gil Park
WTWon Young Tak
Won Young Tak
JPJun Yong Park
Jun Yong Park
YKYoung Oh Kweon
Young Oh Kweon
WCWoo Jin Chung
Woo Jin Chung
WLWon Kee Lee
Won Kee Lee
Background and Aims: Clinical evidence for the benefits of branched-chain amino acids (BCAAs) is lacking in advanced liver disease. We evaluated the potential benefits of long-term oral BCAA supplementation in patients with advanced liver disease. Methods: Liver cirrhosis patients with Child–Pugh (CP) scores from 8 to 10 were prospectively recruited from 13 medical centers. Patients supplemented with 12.45 g of daily BCAA granules over 6 months, and patients consuming a regular diet were assigned to the BCAA and control groups, respectively. The effects of BCAA supplementation were evaluated using the model for end-stage liver disease (MELD) score, CP score, serum albumin, serum bilirubin, incidence of cirrhosis-related events, and event-free survival for 24 months. Results: A total of 124 patients was analyzed: 63 in the BCAA group and 61 in the control group. The MELD score (p = 0.009) and CP score (p = 0.011) significantly improved in the BCAA group compared to the control group over time. However, the levels of serum albumin and bilirubin in the BCAA group did not improve during the study period. The cumulative event-free survival was significantly improved in the BCAA group compared to the control group (HR = 0.389, 95% CI = 0.221–0.684, p < 0.001). Conclusion: Long-term supplementation with oral BCAAs can potentially improve liver function and reduce major complications of cirrhosis in patients with advanced liver disease.

1 January 2012 in The Korean Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
JLJune Sung Lee
June Sung Lee
Lee JS. Korean J Intern Med. 2012 Mar;27(1):13-19. http://dx.doi.org/10.3904/kjim.2012.27.1.13

15 September 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
KKKyung-Ah Kim
Kyung-Ah Kim
JLJune Sung Lee
June Sung Lee
Kyung-Ah Kim and June Sung Lee. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl19272

30 December 2009 in Gut and Liver
Verified
Journal Article
Open access
PDF file
JKJong Hoon Kim
Jong Hoon Kim
JLJune Sung Lee
June Sung Lee
SLSeuk Hyun Lee
Seuk Hyun Lee
WBWon Ki Bae
Won Ki Bae
NKNam-Hoon Kim
Nam-Hoon Kim
YMYoung-Soo Moon
Young-Soo Moon
Kim JH, et al. Gut Liver. 2009 Dec;3(4):292-297. http://dx.doi.org/10.5009/gnl.2009.3.4.292

29 April 2013 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YJYoung-Joo Jin
Young-Joo Jin
JLJin-Woo Lee
Jin-Woo Lee
JLJung Il Lee
Jung Il Lee
SPSang-Hoon Park
Sang-Hoon Park
CPChoong Kee Park
Choong Kee Park
SHSeungbong Han
Seungbong Han
Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800–1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Early virologic response and sustained virologic response (SVR) rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values>0.05) and 2/3 (all P-values>0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤50 and >50), HCV viral load (IU/mL) (≤7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values >0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values >0.05). Adverse event rates were similar between two groups. Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.